Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC)

Targeted Oncology

Volumn 10, Issue 3, 2015, Pages 365-373

  Kwok, C W ^a   Treeck, O ^a   Buchholz, S ^a   Seitz, S ^a   Ortmann, O ^a   Engel, J B ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Combination therapy; LHRH receptor; Targeted therapy; Triple negative breast cancer; Triptorelin

Indexed keywords

AEZS 112; AEZS 129; AEZS 134; AEZS 136; ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; GONADORELIN RECEPTOR; MESSENGER RNA; PERIFOSINE; TRIPTORELIN; UNCLASSIFIED DRUG; ANILINE DERIVATIVE; GONADORELIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHORYLCHOLINE;

ARTICLE; BREAST CANCER CELL LINE; CANCER CELL DESTRUCTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; EC50; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENOME ANALYSIS; GNRH RECEPTOR GENE; HCC1806 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MDA MB 231 CELL LINE; MONOTHERAPY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; AGONISTS; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMISTRY; DNA MUTATIONAL ANALYSIS; DOSE RESPONSE; FEMALE; METABOLISM; TUMOR CELL LINE;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DNA MUTATIONAL ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GONADOTROPIN-RELEASING HORMONE; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLCHOLINE; RECEPTORS, LHRH; TRIPLE NEGATIVE BREAST NEOPLASMS; TRIPTORELIN PAMOATE;

EID: 84940898129     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-014-0340-y     Document Type: Article

References (35)

1. De Laurentiis M, Cianniello D, Caputo R, Stanzione B, Arpino G, Cinieri S et al (2010) Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev 36(Suppl 3):S80–S86
2. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res: Off J Am Assoc Cancer Res 13:2329–2334
3. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res: Off J Am Assoc Cancer Res 13:4429–4434
4. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25–32
5. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer 109:1721–1728
6. Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC, Akslen LA et al (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7:134
7. Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A et al (2001) Hypothalamic hormones and cancer. Front Neuroendocrinol 22:248–291
8. Engel JB, Schally AV (2007) Drug insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab 3:157–167
9. Westphalen S, Kotulla G, Kaiser F, Krauss W, Werning G, Elsasser HP et al (2000) Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines. Int J Oncol 17:1063–1069
10. Schally AV (1999) LH-RH analogues: I. Their impact on reproductive medicine. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol 13:401–409
11. Engel JB, Schally AV, Dietl J, Rieger L, Honig A (2007) Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones. Mol Pharm 4:652–658
12. Schally AV, Nagy A (2003) New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci 72:2305–2320
13. Schally AV, Nagy A (2004) Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab: TEM 15:300–310
14. Buchholz S, Seitz S, Schally AV, Engel JB, Rick FG, Szalontay L et al (2009) Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition. Int J Oncol 35:789–796
15. Fost C, Duwe F, Hellriegel M, Schweyer S, Emons G, Grundker C (2011) Targeted chemotherapy for triple-negative breast cancers via LHRH receptor. Oncol Rep 25:1481–1487
16. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520–529
17. Huober J, Fasching PA, Hanusch C, Rezai M, Eidtmann H, Kittel K et al (2013) Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) +/− bevacizumab—results of the randomised GeparQuinto study (GBG 44). Eur J Cancer 49:2284–2293
18. Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70:440–446
19. Forbes SA, Tang G, Bindal N, Bamford S, Dawson E, Cole C et al (2010) COSMIC (the catalogue of somatic mutations in cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res 38:D652–D657
20. Engel JB, Schally AV, Buchholz S, Seitz S, Emons G, Ortmann O (2012) Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH). Arch Gynecol Obstet 286:437–442
21. Schally AV (1999) Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides 20:1247–1262
22. Fister S, Schlotawa L, Gunthert AR, Emons G, Grundker C (2008) Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells. Gynecol Endocrinol 24:24–29
23. Emons G, Schulz KD (2000) Primary and salvage therapy with LH-RH analogues in ovarian cancer. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer. 153:83–94
24. Ackermans PA, Solosko TA, Spencer EC, Gehman SE, Nammi K, Engel J et al (2012) A user-friendly integrated monitor-adhesive patch for long-term ambulatory electrocardiogram monitoring. J Electrocardiol 45:148–153
25. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N (2009) Triple-negative breast cancer—current status and future directions. Ann Oncol: Off J Eur Soc Med Oncol / ESMO 20:1913–1927
26. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q et al (2010) Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol: Off J Am Soc Clin Oncol 28:1145–1153
27. Wong E, Giandomenico CM (1999) Current status of platinum-based antitumor drugs. Chem Rev 99:2451–2466
28. Hernandez-Aya LF, Gonzalez-Angulo AM (2011) Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist 16:404–414
29. Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M et al (2008) Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res: BCR 10:R101
30. Lopez-Knowles E, O’Toole SA, McNeil CM, Millar EK, Qiu MR, Crea P et al (2010) PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer J Int du Cancer 126:1121–1131
31. Bos JL (1989) ras oncogenes in human cancer: a review. Cancer Res 49:4682–4689
32. Garnett MJ, Marais R (2004) Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6:313–319
33. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954
34. Schubbert S, Shannon K, Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7:295–308
35. Bartholomeusz C, Gonzalez-Angulo AM, Liu P, Hayashi N, Lluch A, Ferrer-Lozano J et al (2012) High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients. Oncologist 17:766–774